Middle East & Africa Human Vaccine Adjuvants Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2030 - Regional Analysis - by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)

No. of Pages: 109    |    Report Code: BMIRE00030455    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Middle East & Africa Human Vaccine Adjuvants Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Middle East & Africa Human Vaccine Adjuvants Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Middle East & Africa Human Vaccine Adjuvants Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Growing focus on immunization is propelling the vaccine production
5.2 Market Opportunities
  • 5.2.1 Growing Pharmaceutical Industry Create Lucrative Growth Opportunities
5.3 Future Trends
  • 5.3.1 Increasing burden of chronic diseases has led to a growing demand for vaccines
5.4 Impact of Drivers and Restraints

6. Middle East & Africa Human Vaccine Adjuvants Market Regional Analysis

6.1 Middle East & Africa Human Vaccine Adjuvants Market Overview
6.2 Middle East & Africa Human Vaccine Adjuvants Market Revenue 2020-2030 (US$ Million)
6.3 Middle East & Africa Human Vaccine Adjuvants Market Forecast Analysis

7. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by Type

7.1 Particulate Adjuvant
  • 7.1.1 Overview
  • 7.1.2 Particulate Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Emulsion Adjuvant
  • 7.2.1 Overview
  • 7.2.2 Emulsion Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Combination Adjuvant
  • 7.3.1 Overview
  • 7.3.2 Combination Adjuvant: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2031 (US$ Million)

8. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by Application

8.1 Influenza
  • 8.1.1 Overview
  • 8.1.2 Influenza: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Hepatitis
  • 8.2.1 Overview
  • 8.2.2 Hepatitis: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Human papilloma virus
  • 8.3.1 Overview
  • 8.3.2 Human papilloma virus: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Human Vaccine Adjuvants Market Analysis – by End User

9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Overview
  • 9.1.2 Human papilloma virus: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2 CMOs and CROs
  • 9.2.1 Overview
  • 9.2.2 Human papilloma virus: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)

10. Middle East & Africa Human Vaccine Adjuvants Market – Middle East and Africa Analysis

10.1 Middle East and Africa
  • 10.1.1 Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Key Country, 2023 and 2030 (%)
  • 10.1.1.1 Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 South Africa: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.1.1 South Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.1.1.1.2 South Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.1.1.1.3 South Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.1.1.2 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.2.1 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.1.1.2.2 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.1.1.2.3 Saudi Arabia: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.1.1.3 UAE: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.3.1 UAE: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.1.1.3.2 UAE: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.1.1.3.3 UAE: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User
  • 10.1.1.4 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
    • 10.1.1.4.1 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.1.1.4.2 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.1.1.4.3 Rest of Middle East and Africa: Middle East & Africa Human Vaccine Adjuvants Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Middle East & Africa Human Vaccine Adjuvants Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Novartis AG
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 CSL Ltd
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Seppic SA
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Croda International Plc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Novavax Inc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Phibro Animal Health Corp
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - M Market

1. Novartis AG 
2. CSL Ltd 
3. Seppic SA 
4. Croda International Plc 
5. Novavax Inc 
6. Phibro Animal Health Corp 

middle-east-and-africa-human-vaccine-adjuvants-market